<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00927459</url>
  </required_header>
  <id_info>
    <org_study_id>TKM-ApoB-001</org_study_id>
    <nct_id>NCT00927459</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Liposomal siRNA in Subjects With High Cholesterol</brief_title>
  <official_title>A Placebo-Controlled, Single-Blind, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRO-040201 in Male and Female Subjects With Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arbutus Biopharma Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arbutus Biopharma Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase 1, single-center, placebo-controlled, single-blind, first-in-human,
      single-ascending dose study in male and female subjects with high cholesterol. A maximum of
      32 subjects is planned for enrollment in this study.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Potential for immune stimulation to interfere with further dose escalation.
  </why_stopped>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of PRO-040201</measure>
    <time_frame>29 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of PRO-040201 in Humans</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics of PRO-040201 in Humans</measure>
    <time_frame>29 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>PRO-040201</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PRO-040201 with placebo control in each cohort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PRO-040201 with placebo control in each cohort</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRO-040201</intervention_name>
    <description>Single dose IV infusion</description>
    <arm_group_label>PRO-040201</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fasting, stable LDL-C ≥ 160 mg/dL

          -  Fasting, stable triglyceride &lt; 400 mg/dL

          -  BMI between 22 and 35 kg/m2, inclusive

          -  Females must be of non-child bearing potential

          -  Males of reproductive potential must agree to practice effective contraception
             throughout the study and for 3 months following infusion

        Exclusion Criteria:

          -  Clinically significant endocrine, hematologic, renal, hepatic, pulmonary, uncontrolled
             psychiatric, or neurologic disease

          -  Cancer within 5 years prior to screening

          -  History of congestive heart failure or chronic heart failure

          -  Uncontrolled cardiac arrhythmias

          -  History of coronary heart disease

          -  Clinically significant abnormal baseline ECG

          -  History of additional risk factors for torsades de pointes

          -  Hepatitis B, C, or HIV positive

          -  Current diagnosis or known history of liver disease

          -  A marked baseline prolongation of QT/QTc interval

          -  Known history of fibromyalgia, myopathy, myositis, rhabdomyolysis, any unexplained
             muscle pain, or a creatine phosphokinase (CPK) &gt;3 x upper limit of normal (ULN) at
             screening

          -  Alanine aminotransferase, AST, GGT, or total bilirubin &gt;2 x ULN at screening

          -  Serum creatinine &gt; 1.5 mg/dL

          -  Systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg on 2
             occasions during screening

          -  Concomitant use of medications that prolongs the QT/QTc interval

          -  Treatment with lipid lowering therapy within 30 days prior to screening

          -  Use of investigational drug within 3 months prior to screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas Logan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medpace Clinical Pharmacology Unit</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medpace Clinical Pharmacology Unit</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2009</study_first_submitted>
  <study_first_submitted_qc>June 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2009</study_first_posted>
  <last_update_submitted>January 21, 2010</last_update_submitted>
  <last_update_submitted_qc>January 21, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Mark Murray, PhD, CEO</name_title>
    <organization>Tekmira Pharmaceuticals Corporation</organization>
  </responsible_party>
  <keyword>cholesterol</keyword>
  <keyword>coronary artery disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

